<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="The elderly and people with underlying diseases are susceptible to" exact="infection" post="and prone to serious outcomes, which may be associated"/>
 <result pre="precisely predict the possible vaccine candidates to prevent against CoV" exact="infection" post="in the future [16]. Currently there is no specific"/>
 <result pre="T cell and B cell memory. In case of SARS-CoV" exact="infection" post="both humoral and cellular immune responses are crucial for"/>
 <result pre="and cellular immune responses are crucial for the clearance of" exact="infection" post="(Fig. 1 ). Recombinant virus vectors work in a"/>
 <result pre="that induces neutralizing antibody and T-cell immune responses against SARS-CoV" exact="infection" post="[19,20] making it an important target for vaccine development."/>
 <result pre="S protein encoding DNA vaccine elicited protective immunity against SARS-CoV" exact="infection" post="in a mouse model by inducing T cell and"/>
 <result pre="The mRNA vaccine manifests the immune responses similar to natural" exact="infection" post="and provides a short synthetic viral mRNA, which is"/>
 <result pre="(mRNA-1273) and another mRNA-based vaccine candidate BNT162, currently in pre-clinical" exact="testing" post="are expected to start in April 2020 [53,56]. However,"/>
 <result pre="virus and later fusion of membranes as well thereby counteracting" exact="infection" post="of virus [58]. S glycoprotein of SARS-CoV which is"/>
 <result pre="antibody thus causing protection of the vaccinated mice to SARS-CoV" exact="infection" post="[64]. Besides this, S protein associated with SARS-CoV is"/>
 <result pre="that elicits antibodies that are not neutralizing. To prevent the" exact="infection" post="from SARS-CoV, with different genotypes RBD containing recombinant proteins"/>
 <result pre="RBD subunit of SARS-CoV-2 would be an important preventive and" exact="treatment" post="strategy that can be tested further in suitable models"/>
 <result pre="been reported [[74], [75], [76]], consequently providing protection subsequent to" exact="infection" post="in animals [77] therefore, this suggest that in vivo"/>
 <result pre="N protein of SARS-CoV-2 do not provide immunity to the" exact="infection" post="[81]. 3.3 Recombinant vector vaccines Recombinant vector vaccines can"/>
 <result pre="[83,94] are some of their limitations which makes their animal" exact="testing" post="challenging and retards their clinical use as a vector"/>
 <result pre="responses similar to natural infection, without posing any risk of" exact="infection" post="and provides long lasting protective immunity. Development of a"/>
 <result pre="due to larger genome size and also requires extensive safety" exact="testing" post="[112]. Furthermore, reversion of the pathogen to the virulent"/>
 <result pre="compared to the lines developed by other means like chemical" exact="treatment" post="and irradiation etc. 3.5 Inactivated virus vaccines Inactivated virus"/>
 <result pre="it induces neutralizing antibodies that prevent host cell attachment and" exact="infection" post="[[127], [128], [129]]. Further nucleic acid based vaccine, showed"/>
 <result pre="pathogen causes diseases in some individuals and mild or no" exact="infection" post="in others. Further, the evaluation of immunity and long-term"/>
 <result pre="coronavirus HCoV-229EJ. Virol.77420032530253812551991 19QinC.WangJ.WeiQ.SheM.MarascoW.A.JiangH.TuX.ZhuH.RenL.GaoH.GuoL.An animal model of SARS produced by" exact="infection" post="of Macaca mulatta with SARS coronavirusThe Journal of Pathology:"/>
 <result pre="miceNature4286982200456156415024391 25ChenN.XiaP.LiS.ZhangT.WangT.T.ZhuJ.RNA sensors of the innate immune system and their" exact="detection" post="of pathogensIUBMB Life695201729730428374903 26EdwardsD.K.JasnyE.YoonH.HorscroftN.SchanenB.GeterT.Fotin-MleczekM.PetschB.WittmanV.Adjuvant effects of a sequence-engineered mRNA"/>
 <result pre="Immunol. Rev.122005185200 33MacGregorR.R.BoyerJ.D.UgenK.E.LacyK.E.GluckmanS.J.BagarazziM.L.ChattergoonM.A.BaineY.HigginsT.J.CiccarelliR.B.ConeyL.R.First human trial of a DNA-based vaccine for" exact="treatment" post="of human immunodeficiency virus type 1 infection: safety and"/>
 <result pre="der VeenR.C.HintonD.R.Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal" exact="infection" post="without eliminating virus from the central nervous systemJ. Virol.69219956846947815531"/>
 <result pre="in miceEmerg. Infect. Dis.11820051312131416110580 124DarnellM.E.PlantE.P.WatanabeH.ByrumR.St ClaireM.WardJ.M.TaylorD.R.Severe acute respiratory syndrome coronavirus" exact="infection" post="in vaccinated ferretsJ. Infect. Dis.196920071329133817922397 125ZhouJ.WangW.ZhongQ.HouW.YangZ.XiaoS.Y.ZhuR.TangZ.WangY.XianQ.TangH.WenL.Immunogenicity, safety, and protective"/>
</results>
